Background. Perindopril is an ACE inhibitor that aids in both blood pressure regulation and
homocysteine reduction. Objectives. Our study aimed to evaluate the results of controlling …

Study design The study was an open, self-controlled study with a minimum of 2 weeks
placebo run-in period followed by 3 months of active treatment with 4 to 8 mg perindopril …

Aim: The aim of our study was to investigate the effectiveness and safety of perindopril in
newly diagnosed or previously treated but uncontrolled adult hypertensive patients …

Abstract Background and Objectives: Optimal control of hypertension reduces the risk of
long-term cardiovascular complications, and current guidelines recommend blood pressure …

Background: The prevalence of hypertension is greater in African Americans, and
management of this condition presents challenges for practicing physicians. Methods: The …

Objective To compare the efficacy and safety of 5 mg perindopril arginine salt and 4 mg
perindopril tert-butylamine salt for patients with mild to moderate essential hypertension …

Background and objectives: Hypertension, one of the major treatable cardiovascular (CV)
risk factors, usually occurs in association with other major risk factors. As well as providing …

Background Inadequate blood pressure (BP) control remains a serious concern worldwide.
Recent evidence suggests that the combination of a calcium channel blocker (CCB) with an …

Objectives: to observe the safety and effect of small dose of perindopril on the patients of
CHD with heart failure and low-normal blood pressure (110mmHg> SBP> 90mmHg) which …

Background: Perindopril, a long-acting angiotensin converting enzyme-inhibitor, reduces
incidence of cardiovascular end points in a wide range of patients. This effect depends on …